The study was aimed to evaluate Simvastatin and Fluvastatin effects on patients with hypercholesterolemia. For 6 months, 141 patients administered Simvastatin (GpA), 100 administered Fluvastatin (GpB) and 100 fluctuated between them (GpC). Post treatment, in GpA, Triglycerides, total Bilirubin (T.BIL), Cholesterol and Low Density Lipoprotein (LDL) were significantly reduced. Alkaline Phosphatase (ALP) and Alanine Aminotransferase (ALT) elevated reduced in females and elevated in males. T.BIL reduced in both males and females. In GpB, Glutamyltransferase elevated and Cholesterol and LDL reduced. Albumin elevated in females and reduced in males and the opposite in Triglycerides. Significant difference between age groups in Albumin, Globulin, and ALT was found. In GpC, Asprtate Aminotransferase (AST) elevated and ALT, Cholesterol, Triglycerides and LDL reduced in all patients. Albumin and ALT elevated in males and reduced in females. Significant difference between age groups in Albumin, T.BIL and AST was found. Fluvastatin or simvastatin had variable effects on lipid parameters in patients with hypercholesterolemia and associated with mild effect on liver. Simvastatin was more effective to reach antihypercholesterolemic goal. Effects were related to gender, age and continuation on the same medication. Patients lab data periodic monitoring during therapy is useful to reach antihypercholesterolemic goal and observe any serious liver parameters elevation.
Introduction
Lipid-lowering drugs are among the most prescribed medications in the world with more than 20 million people prescribed this class of drugs. Since the US Food and Drug Administration (FDA) approved Lovastatin in 1987, statins (3-hydroxy-3-methyl glutaryl coenzyme A [HMG-CoA] reductase inhibitors) have been the most widely used for the treatment of dyslipidemia to reduce the risk of cardiovascular disease. There has been considerable debate in the medical community regarding the clinical significance of the potential differences between the drugs in this class [1] .
It is commonly supposed that statins act by blocking cholesterol synthesis through inhibition of HMG-CoA reductase is the first and rate-limiting step in cholesterol synthesis [2, 3] . Lowering plasma low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) level to the target value is considered essential in the treatment. Currently, 3-hydroxy-3-methylglutaryl coenzyme role in the treatment of hypercholesterolemia. Various A (HMG-CoA) reductase inhibitors (statins) play a central statin trials have shown that lowering plasma cholesterol level in patients with statins can reduce coronary heart diseases (CHD) and total mortality risk [4] [5] [6] .
In recent years, many patients and health professionals have questioned the safety of statins. There have been indications from the media and from clinical experience that some patients refuse to initiate statin therapy while others choose to withdraw from long-term statin treatment because of concerns about safety [7] . The importance of investigating hepatic adverse effects of drugs on the liver lies in the fact that drug-induced hepatotoxicity has become an important public health problem, contributing to more than 50% of acute liver failure cases [8] . Annually dozens of patients with drug induced hepatotoxicity were demonstrated, a fraction of whom requires immediate transplantation because of irreversible damages to their livers. The attention of studying drug hepatotoxicity had increased when a number of fatal hepatic toxicity cases were demonstrated with 2 drugs of the thiazolidinedione antidiabetic agents (troglitazone and rosiglitazone) which caused acute hepatic failure and severe hepatocellular injury [9] [10] [11] . The first clinical studies on HMG-CoA reductase inhibitors reported a low incidence of liver toxicity, but this was followed by observations of a large number of cases on statin therapy with hepatic toxicity [12] . Because of the less number of data concerning the hepatic toxicity of statins and comparing the activity of them, the present study was performed to evaluate the hepatic adverse effects and antihypercholesterolemic effect of statins on liver by measuring and follow up liver parameters in a number of hypercholesterolemic patients who received simvastatin and Fluvastatin. 
Patients and methods

Patients
The selected patients were randomly divided into three groups of hypercholesterolemic 150 patients each. The patients were asked to take part in the study after explaining to them their role in the study. Consent was obtained from each patient before enrolling in the study. Any patient how withdraw from the study at any time his data was removed. 
Methods
The patients were followed up through the database system and medical record files collecting, the laboratory results of lipid parameters tests and liver functions tests on starting treatment and 6 months post treatment using the next laboratory parameters: 
Results
A total of 450 were enrolled in the study, 341 (165 females) patients completed the study. Their ages ranged from 32 to 91 years. 141 (66 females) patients were taking Simvastatin their ages ranged from 32 to 86 years as GpA, 100 (49 females) were taking Fluvastatin their ages ranged from 35 to 91 years as GpB and 100 (50 females) fluctuated randomly between both of Fluvastatin and Simvastatin their ages ranged from 32 to 86 years as GpC. Table 1 shows the effects of the three treatment groups on all patients liver function and blood tests. Table 2 shows the effects of gender on the three treatment groups. Table 3 shows the effects of age on the three treatment groups. 2.4 ± 3 1.6 ± 0.7 0.507 2.1 ± 1.5 2 ± 1.3 2.3 ± 3 0.709 2 ± 0.8 1.8 ± 1.1 1.8 ± 1 0.292 LDL 3.1 ± 0.8 2.9 ± 0.9 2.6 ± 0.8 0.099 2.8 ± 0.7 2.9 ± 0.6 2.9 ± 0.8 0.942 3.5 ± 
Discussion
In contrast to most of the previous studies, this study quantified the differences and similarities of Simvastatin and Fluvastatin, including efficacy and safety, assessed in head-to-head comparison trials and provided pooled estimates where possible. The quantitative results of the lipid-lowering effect of each statin could serve as a quick guide for clinicians. This study identifies heterogeneity among studies and areas with insufficient data where future studies could be focused. The results of the present study indicated significant differences between Simvastatin and Fluvastatin in efficacy and toxicity.
The data of Simvastatin effect obtained in the present study indicate statically significant reductions were found among TG (-0.1%), CHO (-15.5%) and LDL (-20%) and mild but not significant elevation of HDL (6.1%). The data of Fluvastatin effect shows statically significant reductions among CHO (-16.30%) and LDL (-16.90%) that confirm results obtained from other studies [13] [14] [15] [16] but with little difference in change percentage. This may be due to the difference in the culture, design and the study period. But in general, the lipid parameters results shows that the Simvastatin is more affective to reduce the LDL level than Fluvastatin and these results are in consistence with those obtained in many studies [16, 17] . However in Fluvastatin group there were statically significant reductions in age range 31-45 years (-32.30%) than the other groups and that opposite the results obtained by Bruckert et al [18] . That may be due to difference in culture and study design.
Generally in Simvastatin and Fluvastatin groups elevations of most of measured hepatic parameters in the current study were observed. This may indicate that the pattern of hepatotoxicity caused by both of the used drugs is hepatocellular damage (elevation of AST and ALT) and cholestasis (elevation of ALP). However in Simvastatin group statically significant reductions were found among T.BIL, but statically significant elevation was found among ALP in female and reduction in male and more elevation found in ALP in patients >60 years comparing with other age groups. Review of the literature demonstrated controversial effects of Simvastatin on cholesterol and hepatic function, some studies reported an elevations of liver parameters during Simvastatin therapy [12, [19] [20] [21] [22] [23] whereas others studies showed that Simvastatin has no effect on liver parameters [24, 25] . Regarding the fluctuation group, in general for all patients there was significant effect on the lipid parameters less than the use of Simvastatin or Fluvastatin separately. Also there was an elevation of ALT, and significant reduction of LDL in male than in females and no relation between the age and the effect on lipid and liver parameters. No studies could be found in the literature which involves comparison of the effect of fluctuation between these two drugs on lipid and liver parameters. Finally the present study showed more efficacy of Simvastatin over Fluvastatin in lipid lowering but non-significant differences between liver parameters of Simvastatin and Fluvastatin which may indicate that the effect of both Fluvastatin and Simvastatin on the liver may be similar.
Conclusions
The majority of patients receiving Fluvastatin can be successfully converted to Simvastatin without loss of lipid control. In many patients, LDL levels may decrease significantly with this conversion. Simvastatin was more effective than Fluvastatin to reach the antihypercholesterolemic goal. The effect was related to the variables of gender, age, and continuation on the same medication. Periodic monitoring of the lipid parameters and biochemical hepatic parameters during therapy with Fluvastatin and Simvastatin may be of value to reach the antihypercholesterolemic goal and observe any serious elevation of liver parameters.
